ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2011) 25 P25

Comparison of two high dose- bolus vitamin D regimens in women with low vitamin D levels

Ioannis Charopoulos & Steve Orme


Leeds General Infirmary, Leeds, UK.


Aim: To compare the efficacy, tolerability and safety of high doses of i.m. vitamin D2 (ergocalciferol) with oral vitamin D3 (colecalciferol) supplementation in women with low vitamin-D levels.

Design and settings: Of 107 patients (s25(OH)D≤50 nmol/l), aged 21–89 years were recruited in a retrospective audit. Participants were separated in two groups according to serum vitamin D levels. The Group 1 included individuals with serum vitamin D levels 30–50 nmol/l and the Group 2 with more severe depletion (<30 nmol/l). All Group 1 patients (n=65) were treated with three-doses regimen of oral monthly colecalciferol 40.000 IU (n=33) or ergocalciferol 300.000 IU bolus injection regimen (n=32). The Group 2 (n=42) received 300.000 IU oral colecalciferol (n=21) or 300.000 IU i.m. ergocalciferol (n=21). The primary end points were the serum levels in 25(OH)Vit D at 3 and 6 months for the Group 1 and at 6 weeks, 3 months and 6 months for Group 2.

Results: Oral colecalciferol regimen showed significantly greater levels of 25(OH)vit D from i.m. ergocalciferol treatment at 6 weeks, 3 and 6 months in both groups (Group 1 P<0.008, P<0.05; Group 2 P<0.0001, P<0.001 and P<0.05). The mean difference of 25(OH)vit D concentrations from baseline was significantly greater for oral colecalciferol treatment at 6 weeks and 3 months in both groups. Less than 5% of patients on i.m. ergocalciferol treatment achieved levels >50 nmol/l at 6 weeks, 3 and 6 months, whereas in oral treatment, 100 and 75% of individuals obtained >50 nmol/l at 6 weeks and 3 months, respectively.

All patients in the oral colecalciferol regimen with secondary hyperparathyroidism at baseline (45%, n=23) normalized their PTH levels at 3 months, whereas only 49% (41%, n=22) was corrected at 3 months, in the injection ergocalciferol regimen.

No case of hypercalcemia, vitamin D toxicity, hypercalciuria or nephrolithiasis were observed.

Conclusion: The high dose-bolus oral colecalciferol treatment seems more potent than i.m. injection ergocalciferol regimen at least in the treatment of low vitamin D due to nutritional or environmental factors. The bolus 300.000 IU and the monthly 40.000 IU of oral colecalciferol produced higher and sustained increase in serum 25(OH)vit D.

Article tools

My recent searches

No recent searches.